HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.

AuthorsAndrew J Wilson, Ethan Troy-Barnes, Maryam Subhan, Fiona Clark, Rajeev Gupta, Adele K Fielding, Panagiotis Kottaridis, Marc R Mansour, Jenny O'Nions, Elspeth Payne, Naina Chavda, Robert Baker, Kirsty Thomson, Asim Khwaja
JournalBritish journal of haematology (Br J Haematol) Vol. 190 Issue 4 Pg. e189-e191 (08 2020) ISSN: 1365-2141 [Electronic] England
PMID32584418 (Publication Type: Case Reports, Letter)
Chemical References
  • Aniline Compounds
  • Pyrazines
  • gilteritinib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
Topics
  • Adult
  • Aniline Compounds (administration & dosage)
  • COVID-19 (diagnostic imaging, enzymology, genetics)
  • Humans
  • Leukemia, Myeloid, Acute (diagnostic imaging, drug therapy, enzymology, genetics)
  • Male
  • Pyrazines (administration & dosage)
  • Remission Induction
  • SARS-CoV-2
  • fms-Like Tyrosine Kinase 3 (genetics, metabolism)
  • COVID-19 Drug Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: